Avalon Pharmaceuticals Identifies Small Molecule Inhibitors of the Aurora/Centrosome Cancer Pathway that Block PLK3 Protein Function

GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today that it has used AvalonRx®, its biomarker based drug discovery system, to identify small molecule inhibitors of the Aurora/Centrosome pathway, and to reveal the protein targeted by these compounds. Their findings were announced today in a poster presentation entitled “Identification of Small Molecule Inhibitors of the Aurora/Centrosome Pathway,” at the American Association for Cancer Research 2008 Annual Meeting, in San Diego, CA.